PetMedix is pleased to announce a multi-year partnership with Boehringer Ingelheim to develop novel and transformative companion animal antibody therapeutics using PetMedix's proprietary Ky9™ platform.
As part of the collaboration, PetMedix, based in Cambridge, will undertake discovery activities against a number of key targets, and Boehringer Ingelheim will work to develop and bring these therapies to market.
While there are many technologies that have been used to develop human therapeutic antibodies, PetMedix's breakthrough approach is equivalent to one that has resulted in a number of successful, novel therapies for humans. PetMedix is the only company in the world that has brought this innovative approach to veterinary medicine, with its Ky9™ platform able to rapidly and efficiently generate fully canine therapeutic antibodies. This approach saves time and money in drug development, and reduces the risk of certain key adverse events relative to other antibody technologies.
The company, founded in 2018, has grown to employ over 30 staff and expanded into new lab space at the Babraham Research Campus in 2020. The partnering deal with the second largest animal health company globally signifies a big step forward for the PetMedix.
"Boehringer Ingelheim is pleased to be working with PetMedix on this cutting-edge technology as a means to bring innovative new therapies to improve the health of animals globally. PetMedix has a unique expertise and its focus on innovation aligns well with our own," shared James Allan, Global Head of Transaction, Business Development & Licensing, Boehringer Ingelheim Animal Health.
"We are excited to be working with Boehringer Ingelheim on this project as we feel we bring complementary experience and expertise to this partnership. PetMedix has developed the leading pet antibody discovery engine, and it will be through Boehringer Ingelheim's global scale and industry leadership that these novel therapies will best be able to succeed and ultimately benefit animals and - by extension - their owners," said Dr Tom Weaver, CEO of PetMedix.
The health and welfare of pets is closely linked to the health and wellbeing of their human owners, as trends show pets are increasingly valued as family members. PetMedix is developing therapeutics to fill a yawning gap in the provision of precision medicine for pets. Through close collaboration with its counterparts in human health, PetMedix is applying the principles of One Health - the mutual benefits of sharing knowledge, experience and technology between human and animal health with the potential for increased benefits for both. This partnering deal provides the opportunity for these mutual benefits to be realised on a global scale.
Article sourced from: https://www.cambridgenetwork.co.uk/news/petmedix-partners-boehringer-ingelheim
Published on: 12.01.21
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557